Cardiac Allograft Vasculopathy: A Formidable Foe.

J Am Coll Cardiol

Cardiac Transplant Program, Division of Cardiology, Duke University Medical Center, Durham, North Carolina.

Published: July 2019

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.05.028DOI Listing

Publication Analysis

Top Keywords

cardiac allograft
4
allograft vasculopathy
4
vasculopathy formidable
4
formidable foe
4
cardiac
1
vasculopathy
1
formidable
1
foe
1

Similar Publications

Heart failure (HF) remains a significant public health issue, with heart transplantation (HT) being the gold standard treatment for end-stage HF. The increasing use of mechanical circulatory support, particularly left ventricular assist devices (LVADs), as a bridge to transplant (BTT), presents new perspectives for increasingly complex clinical scenarios. This study aimed to compare long-term clinical outcomes in patients in heart failure with reduced ejection fraction (HFrEF) receiving an LVAD as BTT to those undergoing direct-to-transplant (DTT) without mechanical support, focusing on survival and post-transplant complications.

View Article and Find Full Text PDF

Cardiac allograft vasculopathy (CAV) is a major prognosis-limiting factor in patients undergoing orthotopic heart transplantation (HT). Due to the diffuse involvement of the coronary tree, CAV lesions are often not amenable to percutaneous coronary intervention (PCI), leaving coronary artery bypass grafting (CABG) and retransplantation as primary revascularization options. : The latest guidelines from the International Society for Heart and Lung Transplantation (ISHLT) recognize CABG as a viable option but with a downgraded strength of recommendation.

View Article and Find Full Text PDF

Background: Long-term renal allograft acceptance has been achieved in macaques using a transient mixed hematopoetic chimerism protocol, but similar regimens have proven unsuccessful in heart allograft recipients unless a kidney transplant was performed simultaneously. Here, we test whether a modified protocol based on targeting CD154, CD2, and CD28 is sufficient to prolong heart allograft acceptance or promote the expansion of regulatory T cells.

Methods: Eight macaques underwent heterotopic allo-heart transplantation from major histocompatibility complex-mismatched donors.

View Article and Find Full Text PDF

Options for pediatric heart valve replacement.

Future Cardiol

January 2025

Department of Cardiovascular Surgery, Arkansas Children's Hospital, Little Rock, AR, USA.

Heart valve replacement is indicated for children with irreparable heart valve disease. These replacements come in a variety of forms including mechanical, xenograft tissue, allograft tissue, and autograft tissue valves. These options each have unique benefits and risks profiles.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!